Acute promyelocytic leukaemia and acquired α-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients

od Wassenaar, T., Black, J., Kahl, B., Schwartz, B., Longo, W., Mosher, D., Williams, E.
Izdano 2008

Two Diarylurea Electron Transport Inhibitors Reduce Staphylococcus aureus Hemolytic Activity and Protect Cultured Endothelial Cells from Lysis

od Proctor, R. A., Dalal, S. C., Kahl, B., Brar, D., Peters, G., Nichols, W. W.
Izdano 2002

Pharmacodynamic Evaluation of the Activity of Antibiotics against Hemin- and Menadione-Dependent Small-Colony Variants of Staphylococcus aureus in Models of Extracellular (Broth) a...

od Garcia, L. G., Lemaire, S., Kahl, B. C., Becker, K., Proctor, R. A., Denis, O., Tulkens, P. M., Van Bambeke, F.
Izdano 2012

A child with soft-tissue infection and lymphadenitis

od Froböse, N.J., Masjosthusmann, K., Huss, S., Correa-Martinez, C.L., Mellmann, A., Schuler, F., Kahl, B.C., Wittkowski, H., Schaumburg, F.
Izdano u New Microbes New Infect (2020)

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience

od Hong, F., Habermann, T. M., Gordon, L. I., Hochster, H., Gascoyne, R. D., Morrison, V. A., Fisher, R. I., Bartlett, N. L., Stiff, P. J., Cheson, B. D., Crump, M., Horning, S. J., Kahl, B. S.
Izdano u Ann Oncol (2014)

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

od Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Nasta, S., O'Connor, O. A., Shi, H., Boral, A. L., Fisher, R. I.
Izdano u Ann Oncol (2009)

VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study

od Chang, J.E., Carmichael, L.L., Kim, K., Peterson, C., Yang, D.T., Traynor, A.M., Werndli, J. E., Huie, M. S., McFarland, T. A., Volk, M., Blank, J., Callander, N.S., Longo, W.L., Kahl, B.S.
Izdano u Clin Lymphoma Myeloma Leuk (2017)

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study

od Chang, J. E., Peterson, C., Choi, S., Eickhoff, J. C., Kim, K., Yang, D. T., Gilbert, L. A., Rogers, E. S., Werndli, J. E., Huie, M. S., McFarland, T. A., Volk, M., Blank, J., Callander, N. S., Longo, W. L., Kahl, B. S.
Izdano 2011

Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C

od Erbe, A K, Wang, Wei, Grzywacz, B, Ranheim, E A, Hank, J A, Kim, K, Carmichael, L, Seo, S, Mendonca, E A, Song, Y, Hong, F, Gascoyne, R D, Paietta, E, Horning, S H, Kahl, B, Sondel, P M
Izdano 2013

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for Advanced Hodgkin Lymphoma in the Modern Era

od Diefenbach, C. S., Li, H., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Crump, M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Kahl, B. S., Friedberg, J. W., Blum, K. A., Habermann, T. M., Tuscano, J. M., Hoppe, R. T., Horning, S. J., Advani, R. H.
Izdano u Br J Haematol (2015)